オートラス・セラピューティクスに関するコメント

The appointment of Robert W. Azelby, with his extensive experience and track record in building successful biotech companies, is seen as a valuable addition to Autolus's Board as the company moves closer to commercializing its first product.

The significant increase in Autolus Therapeutics' share price and revenue growth has caught the market's attention, signalling optimism. However, despite recent positive returns, the company's long-term loss requires cautious investment consideration.

Dr. Christian Itin, CEO of Autolus, expressed optimism about Leiderman's appointment citing her vast financial, transaction, and operational experience. He also shared the company's anticipation to transition from a development stage to a commercial entity.

Why Join Us?
Pre-market Magic: Wanna know the insider scoop before the market opens? Our talented crew will give you the lowdown on pre-market movements, giving you a sneak peek into the thrill of investing!
FDA Calendar Know-how: Confused about FDA approval processes? Fear not! Our FDA Calendar will turn you into a pharma whiz, keeping you in the loop with crucial timings!
Money Trail: Curious about where the funds are flowing? The Fundraising Tracker '23 is here to spill the beans, ...